Sarizotan

DB06454InvestigationalSmall molecule

Investigated for use/treatment in schizophrenia and schizoaffective disorders and parkinson's disease.

Mechanism: Pharmacologically active on 5-hydroxytryptamine receptor 1A, Dopamine receptor D4, and Dopamine receptor D2
Curator reviewed
Primary indication: Investigated for use/treatment in schizophrenia and schizoaffective disorders and parkinson's disease.Curator reviewed
Formula / weight: C₂₂H₂₁FN₂O · 348.421 g/mol (avg)
Code names: EMD-77697

Resolves to

Compound

Structure

InChIKeyHKFMQJUJWSFOLY-OAQYLSRUSA-NSMILESFC1=CC=C(C=C1)C1=CN=CC(CNC[C@H]2CCC3=CC=CC=C3O2)=C1

Targets

What you can answer from here — as of September 23, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

22+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sarizotan, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.